Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program on July 15, 2026 first-line Kelun Keytruda Merck Non-Small Cell Lung Carcinoma Overall Survival PD-L1-negative PD-L1-positive pembrolizumab Phase III Progression-Free Survival sac-TMT therapeutic autologous dendritic cells TROP2 +